GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Cash Flow for Lease Financing

Implantica AG (OSTO:IMP A SDB) Cash Flow for Lease Financing : kr Mil (TTM As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Cash Flow for Lease Financing?

Implantica AG's Cash Flow for Lease Financing for the six months ended in . 20 was kr0.00 Mil. Implantica AG does not have enough years/quarters to calculate the Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in . 20.

Compared with last quarter (kr0.00 Mil in . 20 ), Implantica AG's Cash Flow for Lease Financing remained the same in . 20 (kr0.00 Mil).


Implantica AG Cash Flow for Lease Financing Historical Data

The historical data trend for Implantica AG's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Cash Flow for Lease Financing Chart

Implantica AG Annual Data
Trend
Cash Flow for Lease Financing

Implantica AG Semi-Annual Data
Cash Flow for Lease Financing

Implantica AG Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.



Implantica AG Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Implantica AG's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Implantica AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines